Developing Durable Drug Formulations & Less Invasive Delivery Mechanisms to the Retina for Improved Patient Compliance
Time: 11:05 am
day: Pre-Conference Workshop
Details:
Many challenges arise when developing therapies for Wet AMD, DME, DR & RVO as therapeutics are aimed to be administered every 2-4 weeks. Due to the aging patient population, this creates burden on patients, their care takers as well as healthcare systems. The industry is moving towards the ultimate goal of developing drugs with longer lasting efficacy that don’t need to be delivered through intravitreal injections as frequently, therefore, reducing patient concerns.
Join this workshop to:
- Discuss the current unmet medical need with developing less invasive retinal delivery administration routes such as topical drugs for diabetic retinopathy and DME
- Different mechanisms of action for topical drugs how to extend drug half-life to achieve slow-release formulation and reduce injections into the retina and uncover how to increase dosage within narrow therapeutic window while achieving safety and efficacy
- Leverage lessons from Genentech’s Port Delivery System (PDS) for Wet AMD to pave the way forward for refillable sustained release implants
- Discussing the potential of anti-VEGF gene therapy as a one-time treatment and the translational challenges when treating retinal neovascularization
- Developing biodegradable sustained release implants to reduce injection frequency to once every six months
- Discussing how to reduce the risk of retinal detachment and inflammation caused by injections whilst improving patient compliance and reducing patient burden on healthcare systems
